KYNB Kyntra Bio Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: KYNB

Price (delayed)

$7.26

Market cap

$29.39M

P/E Ratio

0.18

Dividend/share

N/A

EPS

$40.44

Enterprise value

$59.8M

?
Relative Growth: Rel. Growth: 44
Relative Strength: Rel. Strength: 37
Relative Valuation: Rel. Valuation: 97
Relative Profitability: Rel. Profitability: 47

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor ...

Highlights
The company's revenue rose by 16% QoQ and by 6% YoY
The quick ratio has grown by 8% from the previous quarter
KYNB's equity has surged by 80% year-on-year but it is down by 46% since the previous quarter
The company's debt fell by 49% YoY but it rose by 2.2% QoQ
The gross margin has plunged by 77% YoY and by 55% from the previous quarter
KYNB's gross profit has dropped by 76% year-on-year and by 49% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.fibrogen.com
Peers: ILMN A HBIO PACB

Key stats

What are the main financial stats of KYNB

KYNB stock price

How has the Kyntra Bio stock price performed over time
Intraday
-0.68%
1 week
4.16%
1 month
5.22%
1 year
36.98%
YTD
-17.31%
QTD
7.08%

Financial performance

How have Kyntra Bio's revenue and profit performed over time
Revenue
$7.44M
Gross profit
$3.03M
Operating income
-$44.79M
Net income
$163.62M
Gross margin
40.7%
Net margin
2,199.4%
The gross margin has plunged by 77% YoY and by 55% from the previous quarter
KYNB's gross profit has dropped by 76% year-on-year and by 49% since the previous quarter
Kyntra Bio's operating margin has soared by 64% YoY and by 16% from the previous quarter
KYNB's operating income has surged by 61% year-on-year and by 2.4% since the previous quarter

Price vs fundamentals

How does KYNB's price correlate with its fundamentals

Growth

What is Kyntra Bio's growth rate over time

Valuation

What is Kyntra Bio stock price valuation
P/E
0.18
P/B
N/A
P/S
3.95
EV/EBIT
0.35
EV/EBITDA
0.35
EV/Sales
8.04
The company's EPS fell by 11% QoQ
KYNB's equity has surged by 80% year-on-year but it is down by 46% since the previous quarter
The stock's price to sales (P/S) is 30% less than its 5-year quarterly average of 5.7 and 12% less than its last 4 quarters average of 4.5
The company's revenue rose by 16% QoQ and by 6% YoY

Efficiency

How efficient is Kyntra Bio business performance
The company's return on sales fell by 22% QoQ
KYNB's return on invested capital is up by 7% since the previous quarter

Dividends

What is KYNB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KYNB.

Financial health

How did Kyntra Bio financials performed over time
KYNB's total assets is 8% smaller than its total liabilities
KYNB's current ratio has surged by 79% year-on-year and by 6% since the previous quarter
Kyntra Bio's total liabilities has plunged by 65% YoY but it has increased by 3.3% from the previous quarter
KYNB's debt to equity has plunged by 152% YoY but it is up by 30% from the previous quarter
KYNB's equity has surged by 80% year-on-year but it is down by 46% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.